Northland Capital partners view on Motif Bio PLC (LON:MTFB): Motif has met a very aggressive timetable since listing on AIM last year. The company continues to rapidly progress iclaprim towards marketing approval. The drug is set to fill a major market void in the wake of a major global public health crisis driven by rampant antibiotic resistance. Having already been tested on over a thousand patients, the drug’s safety and efficacy is well supported. If approved, the drug could achieve over $1bn/year in sales. We continue to expect the treatment to be approved and launched in 2018.
|
|
| n Motif announced financial results for the year ended 31 December 2015.
n The Group has had a transformational year since listing on AIM in April 2015. Key highlights included: n Obtaining regulatory approvals (in the US and EU) to commence Phase 3 trials on its flagship antibiotic iclaprim n Raising c. £25m to fund the trials n Appointing Covance to conduct the trials n Obtaining QIDP designation giving iclaprim up to 10 years of U.S. market exclusivity n Obtaining fast-track designation for iclaprim from the U.S. FDA n Preparing trial drug supplies and beginning to dose patients |
|
|
*Northland Capital Partners Ltd., acts as broker to Motif Bio PLC
|
